our vision

Our vision is to be the leading formulation and device development experts reflected in strong partnerships and own specialist commercialisation in niche diseases.

Our strategy is to fully leverage our differentiated technology and skills, maximising value through partnered generic drug-device combinations and enhancing the inhaled performance of existing molecules.
James Ward-Lilley, Chief Executive Officer

our business at a glance

450

employees

c. 200

experienced scientists in our
clinical, regulatory, formulation and device teams

7million+

patients treated with Vectura
technologies in 2017

Our core values

Our patient focus drives what we do and how we do it. We are passionate about improving our patients’ lives every day.

We look to innovate every day. Each one of us is inspired and enabled to improve what we do and how we do it. We keep learning so that we can push the boundaries of what is possible.

We seek to understand each other’s needs consistently, and use our combined knowledge and expertise to enable mutual success in every collaboration.

We enjoy working together to achieve what needs to be done. It is our individual drive to apply our learning and be accountable to others that makes our collaboration so successful.

We have a clear strategy for growth to support our vision

Our strategy is firmly set on growing the business through the development of a strong portfolio, primarily partnered to share the risk and cost of development, and progressively developing assets in niche specialist disease segments.

our market

Market dynamics

Vectura is well placed to succeed in a dynamic and growing airways disease market.